CHC MontLegia — Clinical Trial Site

122 Registered trials

63 Currently recruiting

Organisation

CHC MontLegia

Location

Liege, Belgium

Identifier

ORG-100043333

Address

Boulev. De Patience Et Beajonc 2, 4000, Belgium

Departments

#1003: medical oncology
032005: Pediatric gastroenterology
032007:Oncologie - Hémato-Immunopatho
Breast Hemoto-oncology clinic
Cardiology
Cardiology Department
Center for Reproductive Medicine
Département d'Oncologie/Hématologie
Département d'Oncologie/Hématologie Adulte
Département de Pédiatrie
Department Hématologie et oncologie pédiatrique
Department of Gastroenterology
Department of hemato-oncology
Department of Oncology
Department of Pediatric Hemato-Oncology
Gastro-entérologie
Gastro-enterology
Gastro-enterology and hemato-oncology
Gastro-oncology
Gastroenterology
Gastropediatric
Gastropediatric department
Groupe Sante CHC - Clinique du MontLegia
Groupe Santé CHC Montlégia
Gynécologie-obstétrique
Gynecology
Hémato - oncologie pédiatrique
Hemato - Oncology
Hemato Oncology
Hemato-Oncologie
Hemato-Oncology
Hematology
Hematology Department
Intensive care
Interventional cardiology and intensive care
Medical Oncology
NA
Neonatal Intensive Care Unit
Néphrologie pédiatrique
Neurolog
Neurology
Neurology Department
Oncologie
Oncologie médicale
Oncology
Oncology - Hematology Department
Oncology for pediatrics
Paediatric haemato oncology
Paediatric haemato-oncology
Paediatric Haematology and oncology
Pediatric Cardiology
Pediatric Haemato-oncology
Pediatric Hemato-Oncology
Pediatric hematology and oncology
Pediatric Oncology and Hematology
Pediatrics
Pediatry
Pulmonology

Clinical trials at this site (122)

Search interface

A study to test how well PLENVU®, a bowel cleansing medicine, works in children and teenagers before they have a colonoscopy exam Recruiting

2025-522046-42-00 Colonic disease 5 2026-03-24
Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting

2025-522713-29-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2026-03-12
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting

2025-522873-12-00 ER+, HER2- Advanced Breast Cancer 5 2026-02-24
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad… Recruiting

2025-521124-29-00 Non-Small Cell Lung Cancer 10 2026-02-13
A study to learn more about how well finerenone works, how safe it is, and how it moves into, through, and out of the body compared to place… Recruiting

2024-519829-38-00 Heart failure due to systemic left ventricular systolic 5 2026-01-09
GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran… Recruiting

2024-511437-35-00 Patients aged 18-65 years old with newly diagnosed prev 10 2026-01-05
A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diab… Recruiting

2024-519494-19-00 Nutritional and metabolic diseases 5 2025-12-22
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic … Recruiting

2025-522860-34-00 Small lymphocytic lymphoma (SLL) 5 2025-12-16
A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting

2024-514500-14-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 5 2025-12-15
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
A study to find out how EMPAgliflozin is tolerated and if it helps children and adolescents with chronic KIDNEY disease (EMPA-KIDNEY Kids) Recruiting

2024-512577-27-00 Chronic kidney disease in paediatric patients 5 2025-12-02
Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting

2025-520927-26-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-11-24
A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in pa… Recruiting

2024-511392-15-00 HR+/HER2- advanced breast cancer 5 2025-11-20
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting

2024-514822-21-00 Platinum-resistant Ovarian Cancer 5 2025-10-02
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight:… Recruiting

2024-520210-21-00 Crohn’s Disease 5 2025-09-19
Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer… Recruiting

2024-516982-35-00 Ovarian Cancer 5 2025-09-11
A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's… Recruiting

2023-509391-42-00 Chron's Disease 11 2025-06-02
Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting

2024-514465-18-00 Advanced or Metastatic Non-Squamous NSCLC 9 2025-04-23
A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti… Recruiting

2024-513053-69-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
Treatment of ELectroencephalographic STatus epilepticus After cardiopulmonary Resuscitation-2 (TELSTAR-2): a multicenter randomised clinical… Recruiting

2024-516068-27-01 status epilepticus 5 2025-04-10
Hypertonic lactate after cardiac arrest Recruiting

2023-506031-15-01 post-anoxic brain injury 4 2025-02-18
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting

2023-505077-32-00 Locally-advanced or metastatic non-squamous non-small c 5 2025-01-28
ZELA trial: Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developi… Recruiting

2024-513420-41-00 prematurity in neonates 10 2025-01-09
A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 … Recruiting

2024-513441-36-00 MMRp/ MSS colon cancer 4 2024-11-27